San Antonio conference

janinvan

   Sorry! ....that conference is, of course, in San Antonio!   Is there a talk about triple negative?

TenderIsOurMight

Hello Ladies,

I made a promise to myself to isolate out some of the information on triple negative bc which comes out of the 2008 San Antonio Breast Cancer Conference. It runs December 10-14.

First out are the abstracts: brief summaries by researchers of their findings. We tend to want the clinical trial treatment findings as that is what level we're in in life. But there are many comments on basic science of triple negative bc which are also helpful in a very real way, to show the future and to maintain a decorum of encouragement.

Here is the direct link to the SABC 2008 abstracts: http://www.abstracts2view.com/sabcs/ Please note you need to sign in as a guest to view them, and then you're taken to all abstracts and you select a day, look around for topic (biologic, treatment, adjuvant, advanced) and click on the topic and a pop up window drops down.

On a cursory look this morning, I have bookmarked three abstracts which I plan to review this evening. I will give title and summary on them. I believe copyright laws prohibit regular reproduction of these.

By all means, please also look at the general agenda of SABC: http://www.sabcs.org/ Here lectures by the experts are mentioned, some of which (mainly retroactively if I recall correctly) are viewable and noteworthy. I will try to lend a hand over these next weeks, in between much business and excitement of the holidays and economy impact in general.  

Well, this would be a good time to say to my friends here and elsewhere: "Happy Holidays one and all."

TenderIsOurMight

As mentioned above,

 

1.[3118] Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059

Conclusions: Modest but encouraging single-agent activity was observed with dasatinib in patients with advanced triple-negative breast cancers

 

2.[2120] Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor.

Conclusions: This is the first randomized study of a PARP inhibitor in cancer patients. BSI-201 is safe and well tolerated when given in combination with G/C and adverse events observed were consistent with the known safety profiles of G / C regimens. An updated evaluation of toxicity profile and PARP-1 expression analysis will be presented.

 

3.[2155] Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer.

Conclusion: In this preliminary analysis, D and C followed by sequential X seems to be an active and well-tolerated regimen as first line treatment in patients with locally advanced or metastatic BC

 

4.[1155] Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial.

Discussion: Denosumab reduced bone turnover in breast cancer patients with bone metastases and elevated uNTx despite prior IV BP therapy. Phase 3 trials of denosumab in cancer patients with bone metastases are in progress. 

 

My best to all,

Tender 

 

Edit:  Sorry, my intent is there, yet my computer isnt.T. 

maxgirl

Tender -- Thanks for the quick summaries of the research most interesting to us.  I really appreciate not having to dig for them.  And never mind about the computer!